LONG-TERM EFFICACY OF OCRELIZUMAB IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS: 6.5-STUDY YEARS

Authors
Category Primary study
JournalJournal of Neurology, Neurosurgery and Psychiatry
Year 2022
This article has no abstract
Epistemonikos ID: acffcf897c0f86ede27d89cf7dfd262fc06db1db
First added on: Feb 14, 2025